Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy

Pediatr Pulmonol. 2023 Dec;58(12):3626-3629. doi: 10.1002/ppul.26673. Epub 2023 Sep 26.

Authors

Tommaso Manciulli¹, Silvia Bresci², Jessica Mencarini², Angelo Avarello², Giovanni Taccetti³, Vito Terlizzi³

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
² Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
³ Department of Paediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Center, Florence, Italy.

PMID: 37750598
DOI: 10.1002/ppul.26673

No abstract available

Keywords: CFTR modulator; DRESS; Trikafta; children; mental status; myelotoxicity.

Publication types

Letter

MeSH terms

Aminophenols / adverse effects
Benzodioxoles / adverse effects
Chloride Channel Agonists / adverse effects
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Drug Combinations
Humans
Mutation
Prevalence

Substances

elexacaftor
ivacaftor
tezacaftor
Cystic Fibrosis Transmembrane Conductance Regulator
Aminophenols
Benzodioxoles
Drug Combinations
Chloride Channel Agonists